论文部分内容阅读
2010年8月7日,“现代中药国际化产学研联盟启动暨复方丹参滴丸FDAⅡ期临床试验结果报告会”在京举行,全国人大常委会副委员长桑国卫出席报告会。会议宣布,复方丹参滴丸成为我国首例完成美国FDAⅡ期临床试验,并将进入FDAⅢ期临床试验的中成药。中国工程院院士张伯礼指出,“复方丹参滴丸成功进入FDAⅢ期临床试验阶段,标志着中药国际化迈出了关键和有力的一步。”
On August 7, 2010, the “Symposium on the Internationalization of Production, Learning and Research of Modern Chinese Medicine and the Report on the Results of Phase II Clinical Trial of Compound Danshen Dripping Pills” was held in Beijing. Sang Guowei, vice chairman of the NPC Standing Committee, attended the report. The meeting announced that compound Danshen Dripping Pills has become China’s first completed Phase II clinical trials of the United States FDA, and will enter the FDA phase III clinical trials of proprietary Chinese medicines. Chinese Academy of Engineering Professor Zhang Baili pointed out that “compound Danshen Dripping Pills successfully entered the phase III clinical trials of FDA, marking the internationalization of Chinese medicine has taken a crucial and powerful step.” "